Veracyte Inc
Abierto
SectorSanidad
48.17 1.9
Resumen
Variación precio
24h
Mínimo
46.6
Máximo
47.91
Ingresos | -20M 29M |
|---|---|
Ventas | -1.6M 139M |
P/B Media del Sector | 45.019 49.052 |
BPA | 0.52 |
Margen de beneficios | 20.642 |
Empleados | 755 |
EBITDA | -17M 29M |
Recomendaciones | Comprar |
|---|---|
Estimación a 12 Meses | +0.51% upside |
Próximas Ganancias | 5 ago 2026 |
|---|
Capitalización Mercado | 1.1B 3.8B |
|---|---|
Apertura anterior | 46.27 |
Cierre anterior | 48.17 |
Noticias sobre sentimiento de mercado
By Acuity
50%
50%
146 / 342 Clasificación en Healthcare
Veracyte Inc Gráfico
Resultados pasados no son un indicador fiable de resultados futuros.
Acerca de Veracyte Inc
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.